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Mohammad Reza Nabatchian1*, Hamid Shahriari1 and Mona Shahriari2Abstract
Background: Drug release in a patient’s body is of particular interest to the pharmaceutical industry. One of the
most essential types of drug release is the gradual release based on a behavior, which is called a profile or modified
release. The investigation of the time-oriented quality characteristic is one of the newest topics in the area of product
design. There are already several approaches addressing this issue. In this paper, a mathematical model is proposed to
find the suitable values of the controllable factors in a drug to achieve the profile of the drug release in the patient’s
body.
Results: The proposed method has several advantages over the existing methods.
Conclusion: The authors feel that by adjusting the control factors during the production process the drug release
profile become closer to the reference profile.
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The amount of time it takes a drug to release in a pa-
tient’s body as well as the time it takes to exert its effects
on the target organ are very important factors used to
measure the effectiveness of a drug. If this releasing
manner is not based on a pre-defined profile, it may
cause a reduction of curative properties of the drug and
can even have some negative effects on the patient’s
body. Similarly, in the area of quality engineering, the
time-oriented quality characteristics are also assessed.
The time-oriented profile of the quality characteristic is
specified and the aim of the designer is to find the pre-
defined profile with minimum deviation from the target.
The quality characteristics are then monitored using
the defined profile. In this study, we aim to establish a
logical relationship between these two areas and to apply
a mathematical modeling approach to investigate the
drug release problem in pharmaceutics. In this paper
some basic definitions of drug release and quality engin-
eering are presented and then we introduce the four
existing approaches for these types of problems and* Correspondence: mrnabatchian@dena.kntu.ac.ir
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article, unless otherwise stated.their deficiencies. The proposed method is presented in
the next section. Several examples are provided to
evaluate the suggested model and in the final section,
the conclusions are made.Definitions
In this section some of the basic terms included in the
paper are defined to familiarize the reader with the con-
cepts of the discussion.Drug release
Drug release is an important stage in the drug life
cycle. When the drug is released based on a pre-
defined profile, it is more effective on the patient’s
body. One of the most applicable approaches for
measuring the amount of released drugs is to measure
the plasma concentration of the drug. The drug is con-
sidered effective when the plasma concentration is
somewhere between minimum effective concentration
(MEC) and minimal toxic concentration (MTC) as is
shown in Figure 1 [1-3].
Drugs are usually classified based on the drug release
mechanism as follows:tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Plasma concentration versus time profile [1].
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quickly released in the body. This is particularly suitable
for drugs that need to take affect rapidly such as pain-
killers [1,4].
Modified drug release: In this case by using the
pharmaceutical techniques, the time, the amount and
the target organ for the drug release is determined. The
delayed release and extended release are the methods
being used. In the delayed release the drug is released
after a pre-determined delay. Figure 2 shows the plasma
concentration for this modified release method [1,4].
In the extended release technique, the drug is released
gradually over a longer period of time. It is classified
into two categories: sustained release and controlled re-
lease. In sustained release, the drug is released continu-
ously with a constant rate. In controlled release, the
drug is released intelligently so that the concentrationFigure 2 Plasma concentration versus time profile for an immediate rremains almost constant in the body. Figure 3 shows the
plasma concentration when using this method of drug
release [1,5].
Time-oriented quality characteristics
There are several definitions of the quality characteris-
tics in the quality management literature. The most
comprehensive of them is the degree of adaptability of
the quality characteristic by the user’s requirements [6].
Furthermore, the design phase is the principal stage of a
product life cycle, because the quality is formed in this
stage and control actions at the end of the production
process cannot improve the quality of a product with
poor quality of design [7].
The Taguchi robust design is a famous design proced-
ure. It is an engineering method for optimizing the
product or process condition to minimize the productelease drug and a delayed release drug [1].
Figure 3 Plasma concentration versus time profile for a controlled release formulation [1].
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as: ambient temperature, humidity, air pressure and dir-
ect sunlight [8]. So, a product with high quality and low
cost is being produced. One property of this approach is
to investigate the quality characteristics numerically. In
this approach the quality characteristics are grouped into
three classes as: nominal the best (NTB), larger the bet-
ter (LTB) and smaller the better (STB). Each of these
quality characteristics could be constant or variable over
time [9].
The target value and the specification limits for the
time-oriented quality characteristics are being changed
over time. So, for the design of a product with these
quality characteristics, the parameters are designed such
that the quality characteristics are being as close to their
pre-specified target values as possible.
In this regard, three basic topics need to be introduced.
Design of experiments (DOE)
A collection of statistical methods that are used to find
the influenced factors on a quality characteristic and to
optimize its conditions. There are several types of DOE
techniques including factorial experiments and fractional
factorial experiments [10,11].
Response surface methodology (RSM)
A statistical and mathematical method for modeling,
analyzing and optimizing the problems with response
variables which are directly related to some other inde-
pendent variables [12].
Desirability function
Is one of the common methods to simultaneously
optimize multi response problems. The most applicablemethod of this type is the Derringer and Suich’s which is
defined for several types of quality characteristics as fol-
lows [13]:
NTB quality characteristic:
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In the above equations:
y: value observed for the quality characteristic
T: The target value for quality characteristic applicable
for NTB quality characteristic.
USL: Upper specification Limit of NTB quality
characteristic
LSL: Lower specification Limit of NTB quality
characteristic
yi*: optimum point for LTB quality characteristic and
highest acceptable value for STB quality characteristic
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lowest acceptable value for LTB quality characteristic
r, s: Weight values, positive constants.
Problem definition
The drugs have a pre-determined profile for release based
on the drug’s controlled-release mechanism. The aim in
any drug laboratory is to find optimum adjustment of the
controllable factors, such as material, production machine
settings and so on to produce drugs that achieve the pre-
determined profile as much as possible. Four methods
already exist for parameter design of a drug to achieve its
pre-determined profile:
Contour overlay method
This method is applied by Gohel and Amin [14] to find
the optimal values to the Diclofenac Sodium formula-
tion. The aim is to determine the suitable values for the
three main controllable factors: stirring speed, concen-
tration of CaCl2 and percentage of liquid paraffin, all of
which influence the drug efficacy. The pre-determined
profile of release is defined in advance. Then, the regres-
sion function of the drug release as a response variable
and the above-mentioned control factors as independent
variables is obtained by the least square method. For
each point of time, the response is computed and com-
pared to the pre-specified value. In this method, one
variable is kept fixed and a two dimensional plot is used
to find the optimal values.
The disadvantage of this method is that when the
number of control factors increases, the efficiency of the
method to introduce optimal values decreases.
Profile selection
In situations where the profile properties are hard to
identify, selection of the best profile is done by using the


















Rt: Percentage of drug release obtained from the refer-
ence formulation
Tt: Percentage of drug release obtained from the test
formulation
n: number of observations
The first index, f1 is defined as the dissimilarity index.
As long as its value is small; the profile is close to thereference profile. The second index, f2 is defined as simi-
larity index and when its value is large; the profile is
near to the reference profile [15,16].
MSE minimizing method
This method is applied in three articles. Truong et al.
[17] used this method to determine the optimum values
for control factors of a regenerative drug based on a pro-
file of seven points.
Park et al. [18] used this method to investigate two
quality characteristics separately for six and seven point
profiles. Shin et al. [19] used this method to assess two
quality characteristics separately for eight and eleven
point profiles.
The first step in this method is to gather data and to
calculate the basic statistics such as the mean and the
variance. Then the RSM for these statistics are com-
puted at each point of time. The optimal values for the
control factors are obtained such that the following ob-
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Where:
M^ x; t q
 
: The mean of the responses at time tq.
v^ x; tq
 
: The variance of the responses at time tq.
Tq: The pre-specified target value for the response
variable for the time q.
w: The number of points in time under study.
Method of minimizing the total cost
This method is used by Goethals and Cho [20] and also
the experiment of Gohel and Amin [14] on the Diclufe-
nac Sodium is reassessed. The logic behind this method
is to find the optimal values for control factors that
minimize the following objective function:

















LSLq and USLq: are the lower and the upper specifica-
tion limits for the quality characteristic, respectively.
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sponse variable at time q.
NCq1 and NCq2: are the costs corresponding to being
greater than USL and smaller than LSL, respectively.
L(y (q)): is the quality loss function for the quality
characteristic within the acceptable region, but not on
the target.
w: is the number of time points under study.
The proposed method
The proposed method is a systematic and straightfor-
ward technique for determining the optimum values for
the control factors for a drug. So that in a specified time
interval, the drug release follows its premeditated profile.
This method requires the following steps:
1. Determination of the drug release profile:
Considering the kind of drug and its mechanism of
release, the pharmaceutics design of the release
profile of a drug by consulting the specialist
physicians. To facilitate the comparison between the
standard profile and the drug profile function, some
points on time are considered and the experiments
are run in these points. At each time point, the
target value and the upper and the lower
specification limits are determined. Selection of the
number of points under study is based on the type
of the drug and its life cycle in the patient’s body.
2. Determination of the experiment templates: In this
stage, many controllable factors such as raw material
and production factors for the drug under study are
determined. Several combinations of these
controllable factors are being tested by running the
experiments. One important logic of the DOE is to
find as much as information possible from the
minimum number of experiments. For each
combination of the factor levels at each time point
some data is collected. Then, the data are organized
based on the Table 1. The primary statistics such as
the mean, the variance and the coefficient of
variation for each time point and the covariance
between observations in different time points areTable 1 Experimental format [20]
Run x Y(1) y1
1 Control factor settings y111…y11m y 11
2 y121…y12m y 12
. … …
r y1r1…y1rm y 1r
. … …
n y1n1…y1nm y 1ncalculated. The computational formulas used to



























3. Determination of the relationships among the statistics
and the control factors: By using RSM technique, the
relationships are defined. For the sake of simplicity and
prevention of using data with several scales, the
control factors are coded by linear relationships.
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ð14Þs21 … Y(w) yw s
2
w
s211 … yw11…yw1m yw1 s
2
w1
s212 … yw21…yw2m yw2 s
2
w2
… … … … …
s21r … ywr1…ywrm ywr s
2
wr
… … … … …
s21n … ywn1…ywnm ywn s
2
wn
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In the interest of time and cost, the number of
control factors is reduced before running the
experiments by using any technique such as
screening experiments, as well as the forward,
backward and stepwise regression.
4 Model optimization: Using the desirability function
method, the optimal values for control factors are
determined based on the type of quality
characteristics and their specification limits such
that their values come as close to the target values













































The results are robust as long as the covariancesTable 2 Main control factors influencing Diclufenac
Sodium release
Variable Control factor Level 1 Level 2 Level 3between the observations for each pair of points are
close to zero. So, when there is a deviation in some
time intervals, they would not be transmitted to the
other points.
The other advantage of the proposed method is its
ability to be used for any part of the desirability
function. For instance when we don’t have access to
the entire data and only the mean and the variance
of the observations are available, the covariance part
of the model may be eliminated. Or if the mean of
the observations at each point of time for different
combinations is in hand, only the mean part of the
model is being used. Also, by using the desirability
function and its weighted values, one may use any
indices in some points under study. For the sake of
simplicity, in the examples provided in Section 5,
equal weights are assigned to all statistical indices in




x3 Percentage of liquid paraffin 0% 25% 50%Numerical examples
To illustrate the applications of the proposed method,
seven examples for different drugs are presented in this
section adapted from credible pharmaceutical papers.These examples are solved by the proposed method to
find the optimum values for the control factors of the
drugs. The required material, the methods of pharma-
ceutical experiments and the data for each example are
presented in the stated indicated references.
Example 1
Diclufenac Sodium
The release profile of this drug is investigated by Gohel
[14] and Goethals [20]. The contour overlay and the
minimization of quality loss function methods are intro-
duced in their papers, respectively. This drug has three
main control factors given in Table 2.
The first step is to code the control factors using the
following relationships:
x1 newð Þ ¼ x1−1000500 ; x2 newð Þ ¼
x2−10
5
; x3 newð Þ ¼ x3−2525
In this research, three points of time for the drug release
profile are being investigated with properties shown in
Table 3.
The response surface relationships for the mean, the
variance, the coefficient of variation and the covariance
between each pair of points under study are presented in
the Appendix 1. Optimum values are shown in Table 4.
Example 2
Terazosin HCl dehydrate
The release profile for this drug is investigated by Shin
[19] and the problem is solved by the MSE minimization
method. This experiment has ten control factors as
shown in Table 5.
Noticing the large number of control factors in this
example, five control factors x1, x3, x7, x8 and x10 are
identified as significant control factors by using the step-
wise regression method. The control factors are coded




; i ¼ 1
xi
7:03
; i ¼ 2; 3;…; 10
8><
>:
In this research, 11 points of time of drug release pro-
file are being investigated as presented in Table 6.




Level 1 Level 2 Level 3 Level 4 Level 5
x1 PEO 93.71 100.77 107.77 171.04 234.31
x2 LH-11 0 7.03 14.06 77.33 140.6
x3 Syloid 0 7.03 14.06 77.33 140.6
x4 Ac-Di-Sol 0 7.03 14.06 77.33 140.6
x5 Na-CMC 0 7.03 14.06 77.33 140.6
x6 HEC 0 7.03 14.06 77.33 140.6
x7 NaH2PO4 0 7.03 14.06 77.33 140.6
x8 Citric acid 0 7.03 14.06 77.33 140.6
x9 Pharma
coat 603
0 7.03 14.06 77.33 140.6
x10 Polyox N10 0 7.03 14.06 77.33 140.6
Table 3 The target values and lower and upper values for
example 1
Response Delay after usage LSL Target USL
y1 1 hour 20% 30% 40%
y2 6 hour 50% 60% 70%
y3 8 hour 65% 72.5% 80%
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the variance of the underlying data are presented in




The release profile of this drug is investigated by Siva
[21]. The three main control factors for this drug are
presented in Table 8.
The control factors are coded by the following
relationships:
x1 newð Þ ¼ x1−113 ; x2 newð Þ ¼
x2−36
12
; x3 newð Þ ¼ x3−9030
In this research, five points of time are investigated
from release profile as shown in Table 9.
The RSM relationships for the mean, the variance and
the coefficient of variation for the points in Table 8 are
presented in Appendix 3. By using the desirability func-
tion method the optimum values obtained for control
factors are shown in Table 10.
Example 4
Metformin
The release profile for this drug is investigated by Nagrava
[22]. The three main control factors are defined for this
drug release as shown in Table 11.
The values of the control factors are coded using the
following relationships:
x1 newð Þ ¼ x1−1:7581:25 ; x2 newð Þ ¼
x2−0:25
0:25
; x3 newð Þ ¼ x3−3:751:25
The three points of time for the release profile are in-
vestigated in this research have the properties provided
in Table 12.
The RSM relationships for the mean, the variance and
the coefficient of variation for the data are presented inTable 4 Optimum values for example 1
Variable Control factor Coded value Uncoded value




x3 Percentage of liquid paraffin 1 50%Appendix 4. By using the desirability function method
the optimum values obtained for control factors are
shown in Table 13.
Example 5
Rhinetedin
The release profile of this drug is investigated by Patel
[23]. The two main control factors for this drug are pre-
sented in Table 14.
The control factors are coded by the following
relationships:
x1 newð Þ ¼ x1−672168 ; x2 newð Þ ¼
x2−168
84
In this research three time points are investigated from
release profile are shown in Table 15.
In this example, the index f2 is the measure of similar-
ity between the drug release profile and the target pro-
file. The RSM relationships are presented in Appendix 5
and the optimum values are shown in Table 16.
Example 6
Metoprolol
The release profile for this drug is investigated by Gohel
[24]. The two main control factors defined for this drug
are shown in Table 17.
The control factor values are coded by using the fol-
lowing relationships:
x1 newð Þ ¼ x1−3010 ; x2 newð Þ ¼
x2−20
10
The three points of time for the drug release profile
are presented in Table 18.
In the study of this drug, f2, t50 (the time required for
50% of drug to be released) and mean dissolution time
(MDT) are the measures of the similarity factor between
Table 6 The target values and lower and upper values for example 2
y1 y2 y3 y4 y5 y6 y7 y8 y9 y10 y11
Time 0.5 h 1 h 1.5 h 2 h 3 h 4 h 6 h 8 h 10 h 12 h 24 h
LSL 4.8 8.8 10.24 12.88 18.08 23.84 34.8 41.12 48.24 54.8 65.84
Target 6 11 12.8 16.1 22.6 29.8 43.5 51.4 60.3 68.5 82.3
USL 7.2 13.2 15.36 19.32 27.12 35.76 52.2 61.68 72.36 82.2 98.76
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quired to dissolve half of the drug and the mean dissol-
ution time, respectively. The RSM relationships for the
means and these measures are presented in Appendix 6.
By using the proposed method, the optimum values are
obtained as shown in Table 19.
Comparison of the proposed method and the existing
ones
The disadvantages of the existing methods are:
Contour overlay method:
This method has a limited application and when the
number of variables exceeds from two, the model may
not be optimized unless the additional variables are be-
ing fixed at a constant level.
Profile selection method:
In this method, the number of test profiles is adjusted
based on the experimenter point of view and the best
profile is selected among the existing ones. It is possible
that the optimum values for the control factors may not
be included in these profiles.
MSE minimizing method:
In this method, there is no attention paid to the speci-
fication limits, while in the real world, passing these
limits has substantial penalties.
Minimizing the total cost method:
In this method all deviations from the target values are
evaluated by means of money terms, while in human
problems, e.g. pharmaceutical studies, adverse events
may have human fallout which cannot be measured by
money terms.
The proposed method overcomes all the above
disadvantages.
Conclusions
Investigation of the pharmaceutics problems in an in-
dustrial engineering framework is very constructive. TheTable 7 Optimum values for control factors for example 2
Variable Control factor Coded value Uncoded value
x1 PEO 15.556 203.069
x3 Syloid 0.691 4.858
x7 NaH2PO4 14.748 103.675
X8 Citric acid 0 0
X10 Polyox N10 20 140.6key point here is the problem presentation by the engin-
eering terms. In this research, the drug release problem
which is an important subject of pharmaceutics is being
studied. In this area, applying the complex formulas is
avoided. So, the experts with minimum knowledge of
mathematics and statistics may apply this approach to
solve the pharmaceutics problems. The results of the ex-
amples show the ability of the proposed model for solv-
ing the controlled release problems and to assure that
the intended drug is resolved as its predefined profile.
The simultaneous optimization of drugs with multi
time-oriented quality characteristics is a topic for the fu-
ture research.
Appendix 1
μ1 1hð Þ ¼ 39:929þ 2:365x1−2:206x2−1:959x3
þ 0:202x21 þ 1:971x22−0:912x23−1:389x1x2
þ 0:797x1x3 þ 0:079x2x3
μ2 6hð Þ ¼ 73:368þ 4:388x1−5:031x2−2:379x3
þ0:399x21 þ 0:579x22−0:127x23−1:525x1x2
−0:062x1x3−0:359x2x3





V 1 1hð Þ ¼ 7:31−0:642x1 þ 0:032x2 þ 2:799x3
þ 1:698x21 þ 5:377x22 þ 4:895x23 þ 5:543x1x2
þ 1:893x1x3−0:686x2x3
V 2 6hð Þ ¼ 5:74−1:195x1 þ 1:609x2−5:458x3
þ7:112x21 þ 0:037x22 þ 9:608x23 þ 11:9x1x2
−4:042x1x3 þ 0:98x2x3
V 3 8hð Þ ¼ 11:548−6:216x1 þ 3:632x2−0:354x3
þ 2:053x21 þ 2:293x22 þ 2:581x23−5:282x1x2
þ 2:575x1x3−5:902x2x3Table 8 Main control factors influencing Verapamil HCl
release
Variable Control factor Level 1 Level 2 Level 3
x1 Coating weigh gain 8% 11% 14%
x2 Duration of coating 24 h 36 h 48 h
x3 Amount of plasticizer 60% 90% 120%
Table 9 The target values and lower and upper values for
example 3
y1 y2 y3 y4 y5
Time 2 h 4 h 6 h 9 h 12 h
LSL 13.36% 26.64% 40% 50% 80%
Target 16.7% 33.3% 50% 75% 100%
USL 20.04% 39.96% 60% 90% 120%
Table 11 Main control factors for example 3




x2 Concentration of gellan gum 0% 0.25% 0.5%
x3 Concentration of metformin 2.5% 3.75% 5%





¼ 0:063−0:005x1−0:001x2 þ 0:012x3
þ 0:007x21 þ 0:008x22 þ 0:014x23





¼ 0:04−0:002x1 þ 0:007x2−0:003x3
þ 0:006x21−0:004x22 þ 0:009x23





¼ 0:039−0:009x1 þ 0:008x2 þ 0:002x3
−0:0002x21 þ 0:004x22 þ 0:006x23−0:007x1x2
þ0:002x1x3−0:006x2x3
s12ð Þ 1h−6hð Þ ¼ 1:89þ 2:507x1−0:799x2 þ 0:299x3
þ 0:677x21−2:227x22−4:571x23−2:594x1x2
−0:655x1x3−2:289x2x3





s23ð Þ 6h−8hð Þ ¼ −2:945−1:711x1−1:729x2−3:296x3
þ 2:541x21 þ 2:411x22−2:738x23−0:22x1x2
þ 3:237x1x3 þ 3:732x2x3
Appendix 2
μ1 0:5hð Þ ¼ 4:844−0:039x1 þ 0:023x3−0:006x7−0:005x8
−0:001x10 þ 0:0001x21−0:00007x23 þ 0:00006x27
þ0:00002x28 þ 0:00003x210 þ 0:0006x1x3
V 1 0:5hð Þ ¼ 0:71−0:008x1 þ 0:0001x3−0:00078x7
þ 0:006x8−0:006x10 þ 0:00003x21
þ 0:000006x23 þ 0:00003x27−0:00002x28
þ 0:00004x210−0:00003x1x3Table 10 Optimum values for control factors for example 3
Variable Control factor Coded value Uncoded value
x1 Coating weigh gain −0.6566 9.0302
x2 Duration of coating 0.5152 29.8176
x3 Amount of plasticizer 1 120μ2 1hð Þ ¼ 7:644−0:027x1 þ 0:015x3−0:01x7 þ 0:017x8
−0:014x10 þ 0:0001x21 þ 0:000001x23 þ 0:0001x27
þ0:0002x28 þ 0:0001x210 þ 0:0004x1x3
V 2 1hð Þ ¼ 1:103−0:041x1−0:027x3−0:002x7
þ0:021x8 þ 0:006x10 þ 0:0001x21
þ0:00008x23 þ 0:00002x27−0:00007x28
−0:00002x210 þ 0:0009x1x3





V 3 1:5hð Þ ¼ 0:292þ 0:021x1 þ 0:035x3−0:031x7
þ0:033x8−0:004x10−0:00005x21−0:000009x23
þ0:0002x27−0:0001x28 þ 0:00003x210−0:0009x1x3
μ4 2hð Þ ¼ 8:611þ 0:165x1 þ 0:248x3−0:074x7
þ0:074x8−0:05x10−0:0005x21−0:0007x23
þ0:0006x27 þ 0:0002x28 þ 0:0003x210−0:006x1x3
V 4 2hð Þ ¼ 1:582−0:082x1−0:05x3−0:033x7 þ 0:058x8
þ 0:027x10 þ 0:0003x21 þ 0:0002x23
þ0:0002x27−0:0002x28−0:0001x210 þ 0:002x1x3
μ5 3hð Þ ¼ 12:428þ 0:207x1 þ 0:309x3−0:09x7
þ 0:089x8−0:049x10−0:0006x21−0:0008x23
þ0:0007x27 þ0:0003x28þ0:0004x210−0:008x1x3
V 5 3hð Þ ¼ 1:69−0:078x1−0:033x3−0:021x7 þ 0:052x8
þ 0:033x10 þ 0:0003x21 þ 0:0001x23
þ0:0001x27−0:0002x28−0:0001x210þ 0:001x1x3
μ6 4hð Þ ¼ 16:417þ 0:287x1 þ 0:388x3−0:11x7
þ 0:126x8−0:07x10−0:0008x21−0:001x23
þ0:0009x27þ 0:0003x28þ 0:0005x210−0:011x1x3Table 12 The target values and lower and upper values
for example 4
Response Delay after usage LSL Target USL
y1 0.5 hour 21% 23.5% 26%
y2 3.5 hours 62% 63.5% 65%
y3 8 hours 91% 92.5% 94%
Table 13 Optimum values of control factors for example 4







x2 Concentration of gellan gum −0.9192 0.0202%
x3 Concentration of metformin −1 2.5%
Table 15 The target values and lower and upper
specifications for example 5
Response Delay after usage LSL Target USL
y1 1 hour 26% 32.5% 39%
y2 5 hours 54% 67.5% 81%
y3 10 hours 68% 85% 102%
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http://www.darujps.com/content/22/1/1V 6 4hð Þ ¼ 3:123−0:134x1−0:074x3−0:035x7 þ 0:061x8
þ 0:053x10 þ 0:0005x21 þ 0:0002x23
þ0:0002x27−0:0002x28−0:0002x210þ 0:003x1x3
μ7 6hð Þ ¼ 21:874þ 0:563x1 þ 0:691x3−0:174x7
þ 0:109x8−0:084x10−0:002x21−0:002x23
þ 0:001x27 þ 0:0006x28 þ 0:0007x210−0:02x1x3
V 7 6hð Þ ¼ 4:719−0:22x1−0:104x3−0:056x7 þ 0:073x8
þ 0:105x10 þ 0:0008x21 þ 0:0003x23
þ0:0003x27−0:0002x28−0:0004x210þ 0:005x1x3
μ8 8hð Þ ¼ 28:588þ 0:811x1 þ 0:963x3−0:221x7
þ 0:073x8−0:11x10−0:002x21−0:003x23
þ 0:001x27 þ 0:0007x28 þ 0:001x210−0:03x1x3
V 8 8hð Þ ¼ 5:417−0:226x1−0:064x3−0:072x7 þ 0:061x8
þ 0:158x10 þ 0:0008x21 þ 0:0001x23
þ0:0004x27−0:0002x28−0:0006x210þ0:004x1x3
μ9 10hð Þ ¼ 37:1þ 0:886x1 þ 1:086x3−0:249x7
þ 0:058x8−0:094x10−0:003x21−0:003x23
þ 0:002x27 þ 0:001x28 þ 0:001x210−0:032x1x3
V 9 10hð Þ ¼ 7:351−0:28x1−0:085x3−0:088x7 þ 0:046x8
þ 0:201x10 þ 0:001x21 þ 0:0002x23
þ0:0005x27−0:0002x28−0:0008x210þ0:005x1x3
μ10 12hð Þ ¼ 44:362þ 1:017x1 þ 1:237x3−0:229x7
þ 0:055x8−0:144x10−0:003x21−0:004x23
þ0:001x27 þ 0:0006x28 þ 0:001x210−0:036x1x3
V 10 12hð Þ ¼ 7:482−0:267x1−0:049x3−0:095x7 þ 0:055x8
þ0:217x10 þ 0:001x21 þ 0:00001x23
þ0:0005x27−0:0002x28−0:001x210 þ 0:004x1x3
μ11 24hð Þ ¼ 82:688þ 0:577x1 þ 0:705x3−0:056x7
þ 0:06x8 þ 0:044x10−0:002x21−0:002x23
þ0:004x27−0:00004x28þ0:0001x210−0:02x1x3Table 14 Main control factors for example 5
Variable Control factor Level 1 Level 2 Level 3
x1 Amount of gelucire 43/01 504 672 840
x2 Amount of ethylcellulose 84 168 252V 11 24hð Þ ¼ 7:503−0:104x1−0:025x3−0:097x7−0:005x8
−0:004x10 þ 0:0005x21 þ 0:00004x23
þ0:0006x27−0:0001x28−0:0001x210þ0:001x1x3
Appendix 3
μ1 2hð Þ ¼ 12:986−2:16x1−x2 þ 0:68x3 þ 0:121x21−0:279x22
þ0:221x23 þ 0:038x1x2 þ 0:038x1x3 þ 0:163x2x3
v1 2hð Þ ¼ 1:274þ 0:057x1 þ 0:33x2−0:235x3−0:064x21






¼ 0:082þ 0:013x1 þ 0:017x2−0:015x3
−0:006x21 þ 0:011x22−0:016x23 þ 0:002x1x2
þ0:014x1x3 þ 0:015x2x3
μ2 4hð Þ ¼ 25:121−5:2x1−2x2 þ 1:43x3 þ 0:47x21−0:331x22
þ0:619x23þ0:163x1x2þ0:063x1x3þ0:338x2x3







¼ 0:046þ 0:01x1 þ 0:002x2−0:011x3
−0:013x21 þ 0:025x22−0:009x23−0:004x1x2
þ0:0004x1x3−0:004x2x3
μ3 6hð Þ ¼ 42:938−7:27x1−2:87x2 þ 2:31x3−0:257x21
−0:257x22−0:057x
2
3 þ 0:913x1x2 þ 0:463x1x3
−0:688x2x3













þ0:004x1x3 þ 0:001x2x3Table 16 Optimum values for example 5
Variable Control factor Coded value Uncoded value
x1 Amount of gelucire 43/01 −0.909 657.7288
x2 Amount of ethylcellulose 1 252
Table 17 Main control factors for example 7
Variable Control factor Level 1 Level 2 Level 3
x1 % of xanthan gum 20% 30% 40%
x2 % of Methocel 10% 20% 30%
Table 19 Optimum values for example 7
Variable Control factor Coded value Uncoded value
x1 % of xanthan gum 0.0458 30.458
x2 % of Methocel 0.6726 26.726
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http://www.darujps.com/content/22/1/1μ4 9hð Þ ¼ 67:278−11:37x1−3:02x2 þ 3:27x3−2:541x21
þ 3:709x22−3:841x23 þ 0:125x1x2 þ 0:825x1x3
þ 0:05x2x3
v4 9hð Þ ¼ 3:563þ 0:311x1−0:064x2 þ 0:085x3−0:895x21






¼ 0:027þ 0:007x1 þ 0:002x2−0:002x3−0:001x21
þ0:001x22 þ 0:003x23 þ 0:003x1x2
−0:002x1x3−0:001x2x3
μ5 12hð Þ ¼ 82:395−12:84x1−5:25x2 þ 3:8x3−0:567x21
−0:417x22 þ 0:333x23−0:675x1x2 þ 0:625x1x3
þ0:125x2x3













μ1 0:5hð Þ ¼ 31:153−3:546x1−3:884x2 þ 3:243x3
þ 0:667x21 þ 1:874x22−3:391x23
þ 2:897x1x2−0:767x1x3 þ 1:175x2x3







¼ 0:028þ 0:002x1 þ 0:0004x2−0:016x3
þ0:01x21−0:01x22 þ 0:022x23−0:016x1x2
−0:01x1x3 þ 0:002x2x3Table 18 The target values and lower and upper
specification limits for example 7
Response Delay after usage LSL Target USL
y1 1 hour 15% 17.5% 20%
y2 4 hours 20% 30% 40%
y3 12 hours 60% 65% 70%
t50 - 6 h 7 h 8 h
MDT - 8 h 9 h 10 hμ2 3:5hð Þ ¼ 64:474−6:603x1−4:648x2 þ 3:1x3−0:977x21
þ4:658x22 þ 1:287x23−1:168x1x2−0:65x1x3
−0:705x2x3







¼ 0:011þ 0:001x1 þ 0:003x2−0:001x3
−0:001x21 þ 0:007x22−0:0003x23−0:00003x1x2
−0:004x1x3−0:002x2x3
μ3 8hð Þ ¼ 92:466−4:383x1−2:878x2 þ 1:811x3−1:242x21
þ 2:206x22−0:987x23−1:1x1x2 þ 0:168x1x3
þ 2:018x2x3
v3 8hð Þ ¼ 0:895−0:192x1 þ 0:213x2−0:302x3










μ1 1hð Þ ¼ 37:191−7:918x1−3:955x2 þ 1:148x21−1:432x22
−0:558x1x2








μ2 5hð Þ ¼ 75:29−6:358x1−8:795x2 þ 1:035x21−1:345x22
þ 0:745x1x2






¼ 0:031þ 0:003x1 þ 0:006x2−0:009x21
−0:002x22−0:005x1x2
μ3 10hð Þ ¼ 89:216−8:49x1−7:528x2 þ 3:797x21−1:728x22
−3:195x1x2
v3 10hð Þ ¼ 3:026−0:145x1−1:292x2 þ 2:372x21−1:968x22
þ 0:75x1x2





¼ 0:017þ 0:002x1−0:003x2 þ 0:007x21
−0:004x22−0:003x1x2
f 2value ¼ 50:157þ 7:52x1 þ 9:473x2−5:26x21−1:49x22
−0:66x1x2
Appendix 6
μ1 1hð Þ ¼ 20:778−3:317x1−4:017x2 þ 0:183x21−0:917x22
−0:325x1x2
μ2 4hð Þ ¼ 38:678−4:5x1−5:7x2 þ 1:583x21−1:467x22
−1:425x1x2
μ3 12hð Þ ¼ 68:822−5:483x1−5:5x2 þ 2:317x21−1:333x22
þ 0:15x1x2
μ4 t50ð Þ ¼ 6:222þ x1 þ 1:167x2−0:333x21 þ 0:167x22
μ5 MDTð Þ ¼ 8:222þ 0:767x1 þ 0:933x2−0:333x21
þ 0:267x22−0:1x1x2
μ6 f 2ð Þ ¼ 68:556þ 11:183x1 þ 11:45x2−2:483x21
−3:583x22−1:525x1x2
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